Male Hypogonadism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Hypogonadism refers to the diminished functional activity of the gonads, which are responsible for producing hormones (such as testosterone, estradiol, antimullerian hormone, progesterone, inhibin B, activin) and gametes (eggs or sperm). Male hypogonadism pertains explicitly to a deficiency in testosterone, a vital hormone for sexual, cognitive, and physiological development and functioning. Clinically low testosterone levels can result in the absence of secondary sexual characteristics, infertility, muscle wasting, and other abnormalities. Reduced testosterone levels may stem from abnormalities in the testicles, hypothalamus, or pituitary gland. There are two primary types of hypogonadism:

·       Primary hypogonadism: Also known as primary testicular failure, this type arises from issues within the testicles. Common causes include Klinefelter's syndrome, which involves an abnormality in the sex chromosomes (X and Y), where males typically possess one X and one Y chromosome. Klinefelter's syndrome has two or more X chromosomes and one Y chromosome.

·       Secondary hypogonadism: This form of hypogonadism indicates dysfunction in the hypothalamus or pituitary gland, which are components of the brain that signal the testicles to produce testosterone.

Hypogonadism is characterized by serum testosterone levels below 300 ng/dL in conjunction with at least one clinical sign or symptom. Signs of hypogonadism include the absence or regression of secondary sexual characteristics, anemia, reduced bone mass or bone mineral density, oligospermia, muscle wasting, and abdominal adiposity. Symptoms of post-pubescent hypogonadism comprise sexual dysfunction (such as erectile dysfunction, diminished libido, reduced penile sensation, difficulty achieving orgasm, and decreased ejaculate), decreased energy and stamina, depressed mood, heightened irritability, difficulties in concentration, alterations in cholesterol levels, anemia, osteoporosis, and hot flushes. The primary treatment option for hypogonadism is testosterone replacement therapy.

·       The overall annual incidence of male hypogonadism is estimated to be 16.1 cases per 100,000 person-years, with the highest incidence observed among men aged 35-44 years, at 21.5 cases per 100,000 person-years.

Thelansis’s “Male Hypogonadism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Male Hypogonadism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Male Hypogonadism across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Male Hypogonadism Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Male Hypogonadism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more